Omalizumab

Active substance Omalizumab
Domain Lung diseases
Reason of inclusion in Horizonscan Geneesmiddelen Biosimilar
Main indication Asthma
Extended indication Aanvullende behandeling om de astmacontrole te verbeteren bij patiënten met ernstig persistent allergisch astma.

Product

Current proprietary name Xolair (Novartis)
Proprietary name STI-004
Manufacturer Sorrento Therapeutics
Mechanism of action Interleukin inhibitor

Registration

Registration route Centralised (EMA)
Orphan drug No
Registration phase Clinical trials
Additional comments Fase 2 en Fase 3 studie afgerond in mei 2016. SPC Xolair is verlopen.

Therapeutic value

Therapeutic value Potential equal value
Duration of treatment Not found

Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.